| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6019017 | Experimental Neurology | 2012 | 7 Pages |
Abstract
⺠Glibenclamide (GLIB) is an emerging pharmacotherapy in spinal cord injury (SCI). ⺠In SCI, an impact force delivered laterally causes unilateral primary hemorrhage. ⺠Medially, the same force causes bilateral hemorrhage and 45% larger lesions. ⺠GLIB was highly beneficial with both unilateral and bilateral primary hemorrhage. ⺠The magnitude of benefit from GLIB depended on the extent of primary hemorrhage.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
J. Marc Simard, Phillip G. Popovich, Orest Tsymbalyuk, Volodymyr Gerzanich,